Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

25.19 +0.15 (+0.60%)

Official Closing Price Updated: 6:30 PM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

99 100 Next >

U.S. PMI Data Looms: A Pivotal Moment for the Dollar and Global Markets

November 04, 2025

The financial world is holding its breath as the release of the upcoming U.S. Purchasing Managers' Index (PMI) data draws near. This crucial economic indicator is not merely a snapshot of business...

Via MarketMinute

AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential

November 04, 2025

The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central...

Via TokenRing AI

Topics Artificial Intelligence

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Novo Nordisk Q3 Preview: Analysts See Profit Drop As Obesity Market Cools, Pfizer Tensions Rise ↗

November 04, 2025

Via Stocktwits

Precious Metals Under Pressure: Dollar Rallies, Stocks Retreat, and Rate Outlook Weighs Heavily

November 04, 2025

As of November 4, 2025, the global financial markets are witnessing a significant shift, with a rallying US dollar and a retreating stock market exerting considerable downward pressure on gold and...

Via MarketMinute

Topics Economy Stocks Supply Chain

Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It ↗

November 04, 2025

Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo Nordisk.

Via Benzinga

Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb ↗

November 04, 2025

Novo Nordisk boosts its Metsera bid to $62.20 per share, valuing the company at $10 billion and outbidding Pfizer in the escalating takeover fight.

Via Benzinga

Curious about the most active S&P500 stocks in today's session? ↗

November 04, 2025

Stay informed about the most active stocks in the S&P500 index on Tuesday's session. Discover the stocks that are generating the highest trading volume and driving market activity.

Via Chartmill

Most active stocks in Tuesday's session ↗

November 04, 2025

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active stocks in today's session.

Via Chartmill

Pfizer Q3 Revenue Trends Remain Uneven, Cost Cuts Drive Earnings ↗

November 04, 2025

Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to Goldman Sachs.

Via Benzinga

These S&P500 stocks have an unusual volume in today's session ↗

November 04, 2025

In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Tuesday's session.

Via Chartmill

Palantir Weighs On Wall Street, Bitcoin Slumps 5%: What's Moving Markets Tuesday? ↗

November 04, 2025

Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, offering a convenient excuse to take profits after strong year-to-date...

Via Benzinga

Pfizer (PFE) Q3 2025 Earnings Call Transcript ↗

November 04, 2025

Pfizer (PFE) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Novo Sweetens Its Bid For Metsera, Pledging Up To $10 Billion ↗

November 04, 2025

Novo Nordisk said it would pay up to $10 billion to acquire obesity-focused Metsera, topping Pfizer's recently hiked bid.

Via Investor's Business Daily

Dow Dips Over 400 Points; Pfizer Earnings Top Estimates ↗

November 04, 2025

Via Benzinga

Topics Stocks

Metsera Gets Revised Bids From Pfizer, Novo Nordisk: Here’s Why It Matters ↗

November 04, 2025

Metsera said that it would be entitled to terminate its merger agreement with Pfizer if Novo’s proposal continues to be superior.

Via Stocktwits

Pfizer's Core Drugs Offset COVID Revenue Drop, Lifts 2025 Profit Outlook Despite Tariffs ↗

November 04, 2025

Pfizer beat Q3 estimates with 87 cents EPS, raised 2025 profit guidance, as Eliquis and Vyndaqel growth offset declining COVID product sales.

Via Benzinga

Pfizer’s (NYSE:PFE) Q3 Earnings Results: Revenue In Line With Expectations

November 04, 2025

Global pharmaceutical company Pfizer (NYSE:PFE) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 5.9% year on year to $16.65 billion. On the other hand, the company’s full-year...

Via StockStory

Pfizer Raises Profit Outlook Even As Third-Quarter Sales Decline ↗

November 04, 2025

Pfizer beat third-quarter expectations Tuesday, though both sales and profit fell year over year. The company also hiked its profit view.

Via Investor's Business Daily

Is Eli Lilly a Millionaire Maker? ↗

November 04, 2025

Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider.

Via The Motley Fool

Topics Intellectual Property

Zoetis (NYSE:ZTS) Reports Q3 In Line With Expectations But Stock Drops

November 04, 2025

Animal health company Zoetis (NYSE:ZTS) met Wall Streets revenue expectations in Q3 CY2025, but sales were flat year on year at $2.4 billion. On the other hand, the company’s full-year revenue guidance...

Via StockStory

Pfizer Inc (NYSE:PFE) Reports Q3 2025 Earnings Beat and Raises Full-Year Profit Guidance ↗

November 04, 2025

Pfizer Q3 2025 earnings beat estimates and the company raised its full-year profit guidance, highlighting strong cost management and non-COVID portfolio growth.

Via Chartmill

Topics Earnings

Pfizer Raises Full-Year Earnings Guidance, Q3 Numbers Beat Street Estimates ↗

November 04, 2025

The company noted that it is on track to deliver about $7.2 billion in overall anticipated net cost savings by the end of 2027.

Via Stocktwits

Topics Artificial Intelligence World Trade

Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance

November 04, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Tops EPS Expectations In Q3 2025 Despite Revenue Decline ↗

November 04, 2025

Pfizer reported Q3 2025 revenue of $16.7 billion and adjusted EPS of $0.87, beating expectations and prompting a full-year EPS guidance raise.

Via Talk Markets

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗

November 04, 2025

With yields of up to 7%, this trio of high-yield stocks are all industry-leading companies.

Via The Motley Fool

Topics Energy Stocks

Pfizer Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗

November 04, 2025

Via Benzinga

Uber, AMD And 3 Stocks To Watch Heading Into Tuesday ↗

November 04, 2025

Stock futures trading lower, watch Uber, Upwork, AMD, Starbucks, Pfizer earnings. Starbucks forms China JV. Cramer advises against AT&T.

Via Benzinga

Michael Burry Is Super-Bearish On Palantir — With 5 Million Puts ↗

November 03, 2025

Michael Burry's Scion Asset Management filed an updated 13F showing a new large bearish position in Palantir and Nvidia, among others.

Via Benzinga

Explore the S&P500 index on Monday and find out which stocks are the most active in today's session. ↗

November 03, 2025

Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Monday and uncover the stocks that are leading the way in terms of trading volume and market...

Via Chartmill

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Pfizer (NY:PFE)

All News about Pfizer

Starting at $3.75/week.

Subscribe Today